Correction: Correlations among quality of life, spinal mobility, and disease activity in early-treated axial spondyloarthritis: a single-center cross-sectional study (BMC Rheumatology, (2024), 8, 1, (54), 10.1186/s41927-024-00426-2)

Abstract

Following publication of the original article [1], misalignments were found in Tables 1 and 3, therefore they have been updated. Table 1 has been corrected from: Demographic data To: Demographic data Total (n = 66) ASDAS-CRP < 2.1 (n = 37) ASDAS-CRP ≥ 2.1 (n = 29) P-value Age, years, mean (SD) 49.3 (13.5) 49.08 (14.01) 49.65 (13.13) 0.868 Male sex, n (%) 41 (62.1) 22 (59.46) 19 (65.52) 0.615 BMI, mean (SD) - BMI < 30, n (%) * - BMI ≥ 30, n (%) 25.9 (6.2) 54 (81.8) 12 (18.2) 24.7 (3.57) 34 (91.9) 3 (8.1) 27.5 (8.21) 20 (66.7) 9 (31.3) 0.060 0.017 HLA-B27 positivity, n (%) 44 23 (62.16) 21 (72.41) 0.381 Radiographic change, n (%) 48 25 (67.57) 23 (79.31) 0.288 Smoking, n (%) 10 4 (10.8) 6 (20.69) 0.315 Previous duration of diagnosis before enrollment, years, median (IQR) 8 (4–12) 8 (3–10) 9 (4–15) 0.164 Duration of symptoms prior to treatment, years, mean (SD)* - ≤ 2 years, n (%) - > 2 years, n (%) 1.2 (1.2) 43 (65.2) 23 (34.8) 0.9 (1.1) 29 (78.4) 8 (21.6) 1.6 (1.3) 14 (48.3) 15 (51.7) 0.034 0.011 Peripheral joint involvement, n (%) - TJC-28, mean (SD) - SJC-28, mean (SD) 25 (37.9) 0.4 (1.8) 0.3 (1.6) 12 (32.4) 0.1 (0.3) 0 13 (44.8) 0.8 (2.7) 0.7 (2.5) 0.303 0.020 0.009 Enthesitis, n (%) 36 (54.5) 19 (51.4) 17 (58.6) 0.556 Previous uveitis, n (%) 25 (37.9) 13 (35.1) 12 (41.4) 0.604 Syndesmophyte presence, n (%)* 30 (45.5) 11 (29.7) 19 (65.5) 0.004 The highest grade of sacroiliitis, median (IQR) 3 (2–4) 3 (2–3) 3 (2–4) 0.155 Psoriasis, n (%) Nail abnormalities, n (%) 12 (18.2) 11 (16.7) 8 (21.6) 7 (19.0) 4 (13.8) 4 (13.8) 0.413 0.743 Inflammatory bowel disease (%) 1 (1.5) 0 1 (3.45) 0.439 WBC (x 10^3 cumm), mean (SD)* 7.0 (2.1) 6.1 (1.6) 8.2 (2.1) < 0.001 Lymphocyte count (x 10^3 cumm), mean (SD) 2.0 (0.8) 2.0 (0.9) 2.1 (0.9) 0.661 Hemoglobin (g/dL), mean (SD) 12.7 (1.9) 12.9 (1.8) 12.4 (2.0) 0.274 Platelet count (x 10^3 cumm), mean (SD) 280 (73) 268 (75) 294 (70) 0.164 ESR (mm/Hg), median (IQR)* 28 (15–49) 23 (7–38) 41 (24–67) 0.002 CRP (mg/dL), median (IQR)* 2.5 (0-14.1) 1.5 (0-2.4) 16.2 (7.2–28.9) < 0.001 Concurrent Medication usage, n (%) - NSAIDS - MTX* - SSZ - LEF - Glucocorticoid* Biologic usage, n (%) - Anti TNF - Secukinumab 44 (66.7) 34 (51.5) 56 (84.8) 16 (24.2) 7 (10.6) 16 (24.2) 11 (16.7) 5 (7.6) 20 (54.1) 15 (40.5) 30 (81.1) 6 (16.2) 1 (2.7) 12 (32.4) 9 (24.3) 3 (8.1) 22 (75.9) 19 (65.5) 26 (84.9) 10 (34.5) 6 (20.7) 4 (13.79) 2 (6.9) 2 (6.9) 0.068 0.044 0.493 0.086 0.038 0.079 0.095 1.000 *P-value < 0.05 Table 3 has been updated from: Univariate analysis and multivariate analysis for high disease activity (ASDAS-CRP 2.1) To: Univariate analysis and multivariate analysis for high disease activity (ASDAS-CRP 2.1) Risk factor Univariate analysis Multivariate analysis Odd ratios P-value Odd ratios P-value BMI ≥ 30 5.09 (1.23–21.07) 0.024 6.24 (1.23–31.63) 0.027 HADS-D 8–10 HADS-D ≥ 11 3.67 (0.82–16.43) 9.17 (0.99–84.61) 0.090 0.051 3.55 (0.63–19.86) 8.72 (0.79–95.73) 0.149 0.077 Sleep disturbance 3.02 (1.10–8.28) 0.032 3.18 (0.88–11.51) 0.077 Duration of symptoms prior to treatment > 2 years 3.88 (1.33–11.31) 0.013 7.33 (1.93–27.91) 0.003 Syndesmophyte presence 4.49 (1.58–12.71) 0.003 WBC count 1.000624 (1.000281- 1.000967) < 0.001 The original article [1] has been updated.